"A significant shift in how new food ingredients are introduced to the American market is on the horizon, as the FDA’s proposed reform of the ‘Generally Recognized as Safe’ (GRAS) pathway has successfully navigated White House regulatory review, marking a crucial step towards potentially mandating ingredient notification and enhancing public oversight."
The U.S. Food and Drug Administration (FDA) has reached a pivotal milestone in its effort to reform the regulatory framework governing new food ingredients. A proposed rule aimed at modernizing the "Generally Recognized as Safe" (GRAS) pathway has successfully completed its review by the Office of Information and Regulatory Affairs (OIRA) within the Office of Management and Budget (OMB). This signifies the final procedural hurdle before the rule can be officially published in the Federal Register, initiating a public comment period and setting the stage for potential future changes in how food companies introduce novel substances into the American food supply. The GRAS pathway, a long-standing mechanism in food law, allows manufacturers to self-determine the safety of ingredients for their intended use, often without direct premarket approval from the FDA. While intended to streamline innovation, this self-determination process has raised concerns regarding transparency and comprehensive oversight, prompting the FDA’s proposed reforms.
The regulatory identifier for this proposed rule is RIN 0910-AJ02. The proposal was officially submitted to OIRA by the FDA on December 1, 2025, and has been under review since then. It is crucial to note that clearing OIRA review does not equate to immediate publication or adoption of the rule. The precise text of the cleared proposal has not yet been made public, meaning consumers and industry stakeholders have not seen the specific provisions as they stand after the review. Furthermore, a proposed rule is subject to a mandatory public comment period, during which interested parties can submit feedback. Following this period, the FDA may revise the proposal before issuing a final rule, which will then outline the effective dates and compliance timelines. This multi-stage process underscores the deliberative nature of regulatory reform, ensuring that changes are thoroughly vetted and consider a wide range of perspectives.
The Evolving GRAS Pathway: From Self-Determination to Enhanced Oversight
The GRAS (Generally Recognized as Safe) pathway is a foundational element of U.S. food law, though its intricacies are often unknown to the average consumer. Established under the Federal Food, Drug, and Cosmetic Act, the GRAS provision allows for the marketing of food substances that are "generally recognized, among experts qualified by scientific training and experience to evaluate its safety, as having been công nhận as safe under the conditions of its intended use." For decades, this system has largely relied on a self-affirmation model. Under current practice, a food manufacturer that wishes to introduce a new ingredient can, in many cases, independently determine its safety for its intended application. This determination is typically made through internal assessments or by consulting a panel of experts chosen by the company itself. If the manufacturer reaches the conclusion that the substance is indeed GRAS, it can then proceed to market the ingredient without requiring explicit premarket approval from the FDA.
While this self-determination model offers efficiency by allowing well-characterized ingredients to reach consumers without undue delay, it has also been a source of concern for regulatory bodies and public health advocates. The FDA does offer a voluntary process for companies to submit GRAS notices. Upon receiving such a notice, the agency reviews the submission and may issue a "no-questions letter," indicating that, based on the information provided, the FDA does not have questions regarding the substance’s GRAS status. This voluntary notification procedure was established following a 2016 final rule, replacing an older petition process. However, the submission of a GRAS notice remains optional. Companies are not legally obligated to inform the FDA about their GRAS determinations; they can self-affirm an ingredient’s safety and introduce it into the market without ever notifying the agency.
The consequence of this voluntary system is a significant gap in the complete inventory of substances present in the American food supply. Neither regulatory agencies nor the public have a comprehensive, up-to-date list of all ingredients that have been deemed GRAS, particularly those that have undergone self-affirmation without FDA review. This lack of complete visibility has been a long-standing issue. As far back as 2010, the Government Accountability Office (GAO) reported that the FDA was not required to review all GRAS substances and that companies could make these determinations without the agency’s direct involvement or knowledge. The GAO recommended strengthening oversight to improve food safety and transparency. Conversely, industry groups have often defended the existing arrangement, arguing that it represents a functional system that facilitates the timely introduction of safe and well-understood ingredients to the market.
Provisions on the Horizon: Towards Mandatory Notification and Public Access
Although the exact text of the rule cleared by OIRA has not yet been released, the government has previously outlined its intentions for the proposed reforms. These public descriptions, found in documents like the Unified Agenda of Federal Regulatory and Deregulatory Actions, provide a legitimate basis for understanding the potential direction of the rule, provided the distinction between announced intent and final provisions is maintained.
According to these publicly available descriptions, a key element of the proposed rule is the shift towards mandatory notification for most substances purported to be GRAS in both human and animal food. This would represent a significant departure from the current voluntary system. Under the proposed framework, companies seeking to market a new ingredient as GRAS would be required to submit a notification to the FDA. Certain exemptions would likely be in place, potentially for substances already listed by the FDA, those that have received a "no-questions" letter from the agency, or ingredients covered by existing regulations.
Furthermore, the proposal aims to enhance transparency by requiring the FDA to establish and maintain a publicly accessible inventory of GRAS notices. This inventory would detail the substances that have been notified and the specific conditions under which they are intended for use. Such a public record would allow regulators, researchers, and consumers to have a clearer understanding of the ingredients present in the food supply. The proposal would also aim to clarify the procedures by which the FDA determines that a substance is not GRAS, providing a more defined process for addressing safety concerns. This initiative was initially signaled in the Unified Agenda in September 2025, indicating a multi-year development process.
However, several critical details remain unknown and are subject to the OIRA review process and subsequent public comment. The extent to which the cleared version of the rule may differ from prior descriptions is unclear. The specific modifications made during OIRA review, the proposed compliance timelines for manufacturers, and whether ingredients already on the market under self-affirmed GRAS determinations would be grandfathered into the new system are all significant questions. Additionally, the resources the FDA would need to effectively manage a mandatory notification system are yet to be fully detailed. These specific provisions are crucial for understanding the practical implications of the rule and are not yet public. While the Unified Agenda may provide projected publication dates, these are often aspirational goals rather than firm commitments.
The Practical Impact for Consumers and the Broader Regulatory Landscape
For consumers, the immediate impact of this rulemaking milestone is minimal. Nothing is changing in grocery stores today, and it may be several years before any tangible effects are felt. The GRAS reform is a regulatory process, not an immediate safety action. No ingredients are being removed from the food supply, and no products are being recalled as a direct result of this OIRA clearance. The rulemaking process is intentionally slow, designed to allow for thorough deliberation and public input. Once a proposal is published in the Federal Register, it will undergo a public comment period. Following that, a final rule will be issued, and subsequent compliance dates will be established.
The ultimate practical benefit of the proposed changes lies in increased transparency. By mandating notification and creating a public inventory of GRAS substances, the FDA aims to provide regulators and researchers with a more complete picture of the ingredients entering the food supply. Instead of relying on a partial, voluntary dataset, stakeholders will have access to a more comprehensive universe of substances. This enhanced visibility is the primary public health benefit being pursued. It’s not necessarily about identifying specific unsafe additives at this stage, but rather about establishing a complete record of what is being used.
Consumers who are concerned about specific ingredients in their food currently have recourse through existing channels. Ingredient statements on packaged foods are legally required and disclose the components of a product. The FDA also maintains a public inventory of voluntarily submitted GRAS notices, which can be accessed for information on ingredients that have undergone some level of agency review. For individuals with specific medical conditions or dietary restrictions, consulting with a clinician or a registered dietitian remains the most reliable approach to managing ingredient concerns, as general claims about food additives found online can often be exaggerated or lack scientific substantiation.
The GRAS reform proposal is not an isolated initiative; it is part of a broader context of evolving federal food policy. On August 3, the Department of Health and Human Services (HHS) and the FDA submitted a whitepaper to OIRA proposing a definition for "ultra-processed food" (UPF). Placing a federal definition of UPF under review signifies the administration’s interest in categorizing and potentially regulating these types of foods. While a formal legal definition could enable agencies to write specific rules, reports suggest the administration might opt to adopt an existing research-based definition instead. Similar to the GRAS proposal, the UPF initiative is currently in a proposed stage, which may offer an opportunity for public comment before any definition is finalized.
Taken together, these proposed changes to food ingredient policy represent some of the most significant developments in recent years. However, it is important to reiterate that neither proposal is finalized. Proposed rules can clear OMB review and subsequently stall, undergo substantial revisions after public comment, or even be withdrawn by a future administration. MedicalDaily will continue to monitor these developments and will report on the proposed GRAS rule when it is officially published by the FDA in the Federal Register. At that point, the actual provisions, the deadline for public comments, and the compliance timeline will become clearly defined, moving from inference to concrete information.
